Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Comment by postie1on Aug 15, 2020 9:34pm
213 Views
Post# 31413662

RE:RE:acasti

RE:RE:acasti

If they could just have had their act together

"Doctors warn of lasting heart complications

With new evidence and data on the virus emerging almost weekly, health officials now have another warning: the risk of death from coronavirus-related heart damage seems to be far greater than previously thought, the American Heart Association said.

"Basically this virus can put some patients' bodies on fire, including their hearts," Dr. Dara Kass, an emergency physician at Columbia University Medical School told CNN's Bianna Golodryga on Saturday.

Inflammation of the vascular system and injury to the heart occur in 20% to 30% of hospitalized coronavirus patients and contribute to 40% of deaths, the association said Friday.

Dr. Mitchell Elkind, the association's president, said that the cardiac complications of Covid-19 could be "devastating" and linger after recovery.

The AHA said research indicates coronavirus could lead to heart attacks, acute coronary syndromes, stroke, blood pressure abnormalities, clotting issues, heart muscle inflammation and fatal heartbeat irregularities."

 
<< Previous
Bullboard Posts
Next >>